Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

420 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-12

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971

Urinary Bladder, Overactive

COMPLETED

Toxin Retrospective Study

NCT03042052

Neurogenic Bladder

COMPLETED

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920

Urinary Bladder, Overactive Pelvic Organ Prolapse

UNKNOWN PHASE4

BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

NCT03320850

Urinary Incontinence Overactive Bladder With Urinary Incontinence

COMPLETED PHASE2

An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder

NCT02161159

Urinary Incontinence Urinary Bladder, Overactive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Bladder, Overactive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BOTOX®

Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.

onabotulinumtoxinA

Intervention Type BIOLOGICAL

onabotulinumtoxinA (BOTOX®)100 to 200 U

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

onabotulinumtoxinA

onabotulinumtoxinA (BOTOX®)100 to 200 U

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Botulinum Toxin Type A BOTOX®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with documented idiopathic OAB diagnosis
* Patient was treated with 100-200U of BOTOX® for OAB
* Urodynamics assessment within prior to first BOTOX® injection.

Exclusion Criteria

* Patient had received botulinum toxin formulations other than BOTOX® in the bladder
* Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No